Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.
7d
GlobalData on MSNSupernus’s stock sinks after depression drug fails trialSupernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an ...
Some of our patients often tell us they need to experience some undesirable truth first-hand to believe it. Implied is the ...
St John of God Hospital in Dublin has said it is the first hospital in Ireland to introduce a special treatment for patients ...
Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...
Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase 2b study of SPN-820 in adults with ...
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...
Ketamine is an old anesthesia drug with psychedelic qualities, and it has been getting a lot of attention for its ability to ...
Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...
The depression treatment market is experiencing steady growth, driven by rising mental health awareness, increasing prevalence of depression, and advancements in novel therapies. The market is ...
A new non-invasive treatment for depression, which has been shown to deliver remission for one third of its patients, is to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results